Supplemental Reading for Chapter 1
Basic Principles of Clinical Pharmacology Relevant to Cardiology

William H. Frishman, MD


Cardiac surgery patients may have clinically relevant changes in the pharmacokinetics of frequently used drugs. Drugs Therap Perspect 2009; 25: 23–26.


References for Chapter 5

Alpha- and Beta-Adrenergic Blocking Drugs

William H. Frishman, MD

21. Davis BR, Cutler JA, Furberg CD, et al: Relationship of antihypertensive treatment regimens and change...


52. Frishman WH, Furberg CD, Friedewald WT: β-Adrenergic blockade for survivors of acute myo-


82. Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part VII: new horizons in beta-adrenoceptor blocking thera-


140. Blumenfeld ID, Sealey JE, Manner SJ, et al: β-


References to Chapter 5


367. Han JA, Frishman WH, Sun SW, et al: Cardiovascular and respiratory considerations with pharma-


References for Chapter 6
Central and Peripheral Sympatholytics

Lawrence R. Krakoff, MD
William H. Frishman, MD


References for Chapter 7
Cholinergic and Anticholinergic Drugs

William H. Frishman, MD
B. Robert Meyer, MD

22. Kajima T, Ishii K, Ogata H: Edrophonium as an antagonist of vecuronium-induced neuromusc-
References for Chapter 8
Calcium Channel Blockers

William H. Frishman, MD
Domenic A. Sica, MD

8. Calcium Channel Blockers


76. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American


126. Frishman WH, Hainer JW, Sugg J, and M-FACT Study Group: A factorial study of combination...


143. Epstein E: Calcium antagonists should continue to be used for first-line treatment of hypertension (commentary). *Arch Intern Med* 155:2150, 1995.


References to Chapter 8


177. Charlap S, Frishman WH: Calcium antagonists and


References for Chapter 9
The Renin-Angiotensin Axis

Angiotensin-Converting Enzyme Inhibitors
and Angiotensin Receptor Blockers

Domenic A. Sica, MD
Todd W. B. Gehr, MD
William H. Frishman, MD

18. Burnier M: Angiotensin II type 1-receptor block-
9-2 Cardiovascular Pharmacotherapeutics


References to Chapter 9


73. Zusman RM: Angiotensin-converting enzyme in-

...
References to Chapter 9


Sica DA. Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? *Curr Hypertens Rep* 10:415, 2008.


Gradman AH. Role of angiotensin II type 1 recep-


235. DeQuattro V, Lee D: Fixed-dose combination ther-


306. Bakris GL, Copley JB, Vicknair N, et al: Calcium...


371. Iravaniyan S, Dudley SC Jr. The renin angiotensin aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5 Suppl; S12, 2008.


375. Garg S, Narula J, Marelli C, Cesario D: Role of an-


References to Chapter 9


References for Chapter 10
The Renin-Angiotensin Axis

Direct Renin Inhibition

William H. Frishman, MD
Domenic A. Sica, MD

10.2 | Cardiovascular Pharmacotherapeutics


51. Thaisrivongs S, Pals DT, Kati WM, et al: Difluoros-


64. Bock MG, DiPardo RM, Evans BE, et al.: Renin inhibitors containing hydrophilic groups. Tetra-


Sica D, Gradman A, Lederballe O, et al: Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone and in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Presented at the 15th World Congress of Cardiology, Barcelona, Spain, September 2-6, 2006, p 797.


Sica D, Gradman A, Lederballe O, et al: Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone and in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Presented at the 15th World Congress of Cardiology, Barcelona, Spain, September 2-6, 2006, p 797.


References for Chapter 11
Diuretic Therapy
in Cardiovascular Disease

Domenic A. Sica, MD
Todd W. B. Gehr, MD
William H. Frishman, MD


References to Chapter 11 11-3


11-4  Cardiovascular Pharmacotherapeutics

111. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 213:1143, 1970.
References to Chapter 11


References for Chapter 12
Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies

Domenic A. Sica, MD
William H. Frishman, MD


References to Chapter 12


111. Chen WC, Fu XX, Pan ZJ, Qian SZ: ECG changes in early stage of magnesium deficiency. Am Heart J 104:1115, 1982.


160. Cavusoglu E, Chopra V, Gupta A, et al: Relation of...


References for Chapter 13
Inotropic Agents

Thierry H. LeJemtel, MD
Marc Klapholz, MD
William H. Frishman, MD

49. Williamson KM, Thrasher KA, Fulton KB, et al:


References for Chapter 14
The Organic Nitrates and Nitroprusside

Jonathan Abrams, MD
William H. Frishman, MD

20. Chiariello M, Gold HK, Leinbach RC, et al: Com-
References to Chapter 14


101. Steering Committee, Transdermal Nitroglycerin Cooperative Study: Acute and chronic antiangiinal efficacy in continuous twenty-four hour application of transdermal nitroglycerin. *Am J Cardiol*


129. Mann T, Cohn P, Holman BL, et al: Effect of nitroprusside on regional myocardial blood flow in


References for Chapter 15

Ranolazine

A Piperazine Derivative

William H. Frishman, MD
James J. Nawarskas, PharmD
Joe R. Anderson, PharmD

18. Lopaschuk GD, Belke DD, Gamble J, et al. Regu-


55. CV Therapeutics, Inc. CV Therapeutics announces preclinical data evaluating ranolazine and dobutamine in a model of CHF. Available at http://www.cvt.com.


References for Chapter 17
Antiarrhythmic Drugs

Peter Zimetbaum, MD
Peter R. Kowey, MD
Eric L. Michelson, MD

49. Kosoglu T, Roci ML, Vlasses PH: Trimethoprim...


77. Nakabayashi H, Ito T, Iwaga T, et al: Disopyramide induces insulin secretion and plasma glucose di-
92. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myo-
107. Horowitz JD, Anavekar SN, Morris PM, et al: Comparative trial of mexiletine and lidocaine in treat-
References to Chapter 17


References to Chapter 17


242b. Garcia D, Cheng-Lai A: Dronedarone: a new anti-


291. specter MJ, Schweizer E, Goldman RH: Studies on magnesium’s mechanism of action in digi-


295. Dyckner T, Wester PO: Ventricular extrasystoles and intracellular electrolytes before and after po-


82. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329, 1996.
96. Hanjis C, Frishman WH, Lerner RG: Aspirin resis-


122. Taniuchi M, Kurz HI, Lasala JM: Randomized


160b. Wiviott SD, Mega JL: Another step on the road to...


180. O’Donoghue M, Antman EM, Braunwald E, et al: The efficacy and safety of prasugrel with and with-


236. van’t Hof AWJ, Valgimigli M: Defining the role of platelet glycoprotein receptor inhibitors in STEMI. Focus on tirofiban. Drugs 69; 85, 2009.


cott, 1992:837.


340. Jones A, Gecky CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunol-


360 Theroux P, Perez-Villa F, Waters D, et al: A ran-
domized double-blind comparison of two doses of Hirulog or heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132, 1995.


380. SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA
293: 690, 2005.
388a. Ozer N, Cam N, Tangurek B, et al: The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose re-


403. Warkentin TE: Venous thromboembolism in hepar-


405. Van den Bessellar AMHP, Lewis SM, Mannucci PM: Status of present and candidate international reference preparations (IRP) of thromboplastins for the prothrombin time: A report of the subcom-

406. Cannegeiter SC, Rosendaal FR: Optimal oral anticoagu-


417. Veterans Administration Cooperative Study: Anticoagu-


454. Meadows TA, Bhatt DL: Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100:
References to Chapter 18


522a. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators: Rivaroxaban – once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. *Am Heart J* 159: 340, 2010.


References for Chapter 19
Thrombolytic Agents

Robert Forman, MD
William H. Frishman, MD

20. ISIS-2 (Second International Study of Infarct Sur-


41. Stenestrand U, Lindback J, Wallentin L for the RIKS-HIA Registry: Long-term outcome of pri-
mary percutaneous coronary intervention vs pre-
hospital and in-hospital thrombolysis for patients
with ST-elevation myocardial infarction. JAMA
42. Chesboro JH, Knatterud G, Roberts R, et al:
Thrombolysis in myocardial infarction (TIMI)
trial, phase 1: A comparison between intravenous
and tissue plasminogen activator and intravenous
43. Dalen JE: Six and twelve month follow-up of phase
1 thrombolysis in myocardial infarction (TIMI)
44. The GUSTO angiographic investigators: The effects
of tissue plasminogen activator, streptokinase, or
both on coronary artery patency, ventricular func-
tion and survival after acute myocardial infarction.
45. Gillis JC, Wagstaff AJ, Goa KL: Alteplase. Reap-
proval of its pharmacologic properties and therapeu-
tic uses in acute myocardial infarction. Drugs
of 100-mg of double-bolus alteplase in achieving
complete perfusion in the treatment of acute myo-
47. Smalling RW, Bode C, Kalbfleisch J, et al and RAP-
ID investigators: More rapid, complete, and stable
coronary thrombolysis with bolus administration
of alteplase compared with alteplase infusion in
acute myocardial infarction. Circulation 91:2725,
1995.
48. Cannon CP, McCabe CH, Gibson CM, et al and
TIMI 10A investigators. TNK-tissue plasminogen
activator in acute myocardial infarction. Results
of thrombolysis in myocardial infarction (TIMI) 10A
49. Cannon CP, Gibson CM, McCabe CH, et al for
TIMI 10B investigators. TNK-tissue plasminogen
activator compared with front loaded alteplase in
acute myocardial infarction. Circulation 98:2805,
1998.
50. Gibson CM, Murphy SA, Kirtane AJ et al. Associa-
tion of duration of symptoms at presentation with
angiographic and clinical outcomes after fibrino-
litic therapy in patients with ST-segment elevation
myocardial infarction. J Am Coll Cardiol 44:980,
2004.
51. Goldman LE, Eisenberg MJ: Identification and
management of patients with failed thrombolysis
after acute myocardial infarction. Am Intern Med
52. Ohman EM, Califf RM, Topol EJ, et al: Consequ-
ences of reocclusion after successful reperfusion
therapy in acute myocardial infarction. Circulation
of the use of coronary angiography and revascular-
ization after thrombolysis for acute myocardial
54. Barbarsh GI, Birnbaum Y, Bogaerts K, et al: Treat-
ment of reinfarction after thrombolytic therapy for
acute myocardial infarction. An analysis of outcome
and treatment choices in the Global Utilization of
Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries (GUSTO I) and
Assessment of the Safety of a New Thrombolytic
55. White HD: Thrombolytic treatment for recurrent
myocardial infarction. Avoid repeating streptoki-
56. Barbash GI, Hod H, Roth A. et al: Repeat infusions
of recombinant tissue-type plasminogen activator
in patients with acute myocardial infarction and
recurrent myocardial ischemia. J Am Coll Cardiol
57. Wijeysundera HC, Vijayaraghavan R, Brahajmee K
et al. Rescue angioplasty or repeat fibrinolysis after
failed therapy for ST-segment myocardial infarc-
tion. A meta-analysis of randomized trials. J Am
perfusion grade 3 but not grade 2 results
improve outcome after thrombolysis for myocardial
infarction. Ventriculographic enzymatic, and
electrocardiographic evidence from the TEAM-3
59. Simes R, Topol EJ, Holmes DR: Link between an-
giographic substudy and mortality outcomes in a
large randomized trial of myocardial reperfusion.
Importance of early and complete infarct artery re-
60. Gibbons CM, Murphy SA, Rizzo MJ et al: Rela-
tionship between TIMI frame count and clinical
outcomes after thrombolytic administration. Cir-
61. Grines CL, DeMaria AN: Optimal utilization of
thrombolytic therapy for acute myocardial infarc-
tion: Concepts and controversies. J Am Coll Cardiol
62. Fibrinolytic Therapy Trialists (FTT) Collaborative
Group: Indications for fibrinolytic therapy in sus-
pected acute myocardial infarction: Collaborative
overview of early mortality and major morbidity
in results from all randomized trials of more than
63. The TIMI III B Investigators: Effects of tissue plas-
minogen activator and comparison of early invasive
and conservative strategies in unstable angina

References to Chapter 19 19-3


89. Granger CB, Becker R, Tracy RP, et al for the GUSTO-I Hemostasis Substudy Group: Thrombin generation, inhibition and clinical outcomes in pa-


136. Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis


References for Chapter 20
Lipid-Lowering Drugs

William H. Frishman, MD
Wilbert S. Aronow, MD


87. Solano MP, Goldberg RB: Management of dyslipid-


167. Lipid Research Clinics Program: The Lipid Re-


194. Gordon DJ, Knoke J, Probstfield JL, et al, for the Lipid Research Clinics Program: High-density li-


Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors


The Lovastatin Pravastatin Study Group: A multi-


423. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major non-cardiac vascular surgery. *Circulation* 107: 1848,
20.03.


449. Altschul R, Hoffer A, Stephen JD: Influence of


475. Elam MB, Hunninghake DB, Davis KB, et al: Effect of niacin on lipid and lipoprotein levels and...


557. Goldberg AC, Ostlund RE, Bateman JH, et al: Effect of plant stanol tablets on low-density lipo-


586. Nissen SE, Tuzcu EM, Brewer HB, et al for the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators: Effect of ACAT inhibi-
tion on the progression of coronary atherosclerosis. 

587. Meuwese MC, Franssen R, Stroes ESG, Kastelein JJP: And then there were acyl coenzyme A: cholesteryl acyl transferase inhibitors. 


592. Tall A: Plasma cholesteryl ester transfer protein. 

593. Clark R, Ruggeri R, Cunningham D, Bamberger M. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. 


599. McKenney JM, Davidson MH, Shear CL, Revkin JH, Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below average high-density lipoprotein cholesterol levels on a background of atorvastatin. 


604. Tall AR: CETP inhibitors to increase HDL cholesterol levels. 

605. Sviridov D, Nestel PJ: Genetic factors affecting HDL levels, structure, metabolism and function. 

606. Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. 


608. Frishman WH, Barkowski RS: Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair? 


611. Manolio T. Novel risk markers and clinical prac-
References to Chapter 20


652. Lewis B: Relation of high-density lipoproteins to coronary artery disease. Am J Cardiol 52:5B, 1983.


compound NO-1886 elevates plasma high-density lipoprotein cholesterol levels in hamsters and rabbits by increasing lipoprotein lipase without any effect on cholesterol ester transfer protein activity. *Metabolism* 46:257, 1997.


703. Peterson SJ, Frishman WH: Targeting heme oxygenase: therapeutic implications for diseases of the


References for Chapter 21

New Aspects of Combination Therapy

Focus on Hypertension

Michael A. Weber, MD


References for Chapter 22
Pharmacotherapy for Smoking Cessation

William H. Frishman, MD


165. Nissen SE, Nicholls SJ, Wolski K, et al for the


195. Leischow SJ: Setting the national tobacco control...


References for Chapter 23
Pharmacotherapy of Obesity

William H. Frishman, MD
Harrriette R. Mogul, MD, MPH
Stephen J. Peterson, MD


References to Chapter 23

23-3


107. Mantzoros CS: The role of leptin in human obesity and disease: A review of current evidence. *Ann In-


23-6

Cardiovascular Pharmacotherapeutics


159. Mather KJ, Verma S, Anderson TJ: Improved endo-


References for Chapter 24
Heart Disease and Treatment of Diabetes Mellitus

Irene A. Weiss, MD
Guy Valiquette, MD
Monica D. Schwarcz, MD
William H. Frishman, MD


40. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. *Dia-


References for Chapter 25
Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension

Warren D. Rosenblum, MD
William H. Frishman, MD

25-2  

Cardiovascular Pharmacotherapeutics  


44. Higenbottam TW, Spiegelhalter D, Scott JP, et al: Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hy-


References to Chapter 25

25-5


129. Haynes WG, Waugh CJ, Dockrell MEC, et al: Mod-


147. Ueno M, Miyauchi T, Sakai S, Goto K: The combined treatment of oral endothelin (ET)-A receptor antagonist and oral prostacyclin (PGI2) analog is more effective in ameliorating pulmonary hypertension (PH) and right ventricular (RV) hypertrophy than each drug alone in rats (abstr). Circulation 100 (Suppl I):I, 1999.


151. 913-921.


156. Galili N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary hypertension:
References to Chapter 25


References for Chapter 26
Selective and Nonselective Dopamine-Receptor Agonists

William H. Frishman, MD
Chandrasekar Palaniswamy, MD


46. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pi-


19. Elkayam U, Silver MA, Burger AJ, Horton DP. The effect of short-term therapy with nesiritide (B-type natriuretic peptide) or dobutamine on long-term...


References for Chapter 28
Vasopressin and Vasopressin Receptor Antagonists

William H. Frishman, MD
Marc Klapholz, MD
Gerard Oghlakian, MD
Jacqueline M. Cook, MD

21. Andrews CE, Brenner BM: Relative contributions of arginine vasopressin and angiotensin II to maintenance of systemic arterial pressure in the an-


28-4  Cardiovascular Pharmacotherapeutics

can Heart Assn, 2008: 70.


References for Chapter 29
Drug-Eluting Stents

James J. Nawarskas, PharmD
Mark J. Ricciardi, MD

46. Wykrzykowska JJ, Onuma Y, Serruys P. Advances in stent drug delivery: the future is in bioabsorb-


References to Chapter 29 29-5


References for Chapter 30

Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease

William H. Frishman, MD


68. Ullah MF, Khan MW: Food as medicine: potential...


98. O’Keefe J, Harris W: Omega-3 fatty acids: Time


122. Sinatra ST, Frishman WH, Peterson SJ, Lin G: Use of alternative/complementary medicine in treating cardiovascular disease. In Frishman WH, Sonnen-


152. Clinical Trial: Trial to identify the anti-blood-clotting compounds in garlic. www.clinicaltrials.gov/ct.


180. Whitchor NT, Mamdani R: Homeopathy with a special focus on treatment of cardiovascular dis-
30-8  *Cardiovascular Pharmacotherapeutics*


74. Lin JC, Quasny HA. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. *Pharmacotherapy.* 17:626, 1997.


143. Schmidt MS, Benyunes MG, Bjornsson TD, et al. In-


